Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2167-2173

  Krzakowski, Maciej ^a   Ramlau, Rodryg ^a   Jassem, Jacek ^a   Szczesna, Aleksandra ^a   Zatloukal, Petr ^a   Von Pawel, Joachim ^a   Sun, Xushan ^a   Bennouna, Jaafar ^a   Santoro, Armando ^a   Biesma, Bonne ^a   Delgado, François M ^a   Salhi, Yacine ^a   Vaissiere, Nathalie ^a   Hansen, Olfred ^a   Tan, Eng Huat ^a   Quoix, Elisabeth ^a   Garrido, Pilar ^a   Douillard, Jean Yves ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; VINFLUNINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PLATINUM DERIVATIVE; TAXOID; VINBLASTINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EUROPE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SINGAPORE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM COMPOUNDS; QUALITY OF LIFE; SINGAPORE; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 77952316743     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.4146     Document Type: Article

References (26)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
2. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
3. Jacquesy JC, Fahy J: Cancer: Superacidic generation of new antitumour agents, in Torrence PF (ed): Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease. New York, NY, John Wiley & Sons, 2000, pp 227-245
4. Etiévant C, Barret JM, Kruczynski A: Vin- flunine (20′, 20′-difluoro-3′, 4′-dihydrovinorelbine) a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 16:3-7, 1998
5. Ngan VK, Bellman K, Hill BT, et al: Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60:225-232, 2001 (Pubitemid 32595250)
6. Jean-Decoster C, Brichese L, Barret JM, et al: VFL, a new Vinca alkaloid: Cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anti-Cancer Drugs 10:537-543, 1999 (Pubitemid 29410800)
7. Lobert S, Ingram JW, Hill B: A comparison of thermodynamic parameters for vinorelbine and vinflunine induced tubuline self-association by sedimentation velocity. Molecular Pharmacol 53:908-915, 1998 (Pubitemid 28244079)
8. Bennouna J, Breton JL, Tourani JP, et al: Vinflunine an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: Results of a phase II study. Br J Cancer 22:1383-1388, 2006 (Pubitemid 43772270)
9. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomised trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000 (Pubitemid 30324363)
10. Fossella FV, DeVore R, Kerr RN, et al: Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000 (Pubitemid 30415821)
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Nat Can Inst 92:205-216, 2000 (Pubitemid 30099779)
12. Pfister DG, Johnson DH, Azzoli CG: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guide line update. J Clin Oncol 22:330-353, 2004 (Pubitemid 41095099)
13. National Comprehensive Cancer Network: Clinical Practice Guideline in Oncology, version V2: 2006 - Non-small-cell lung cancer. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site
14. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001 (Pubitemid 32230875)
15. Hotta K, Fujiwara Y, Kiura K, et al: Relationship between response and survival in more than 50,000 patients with advanced non-small-cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2:402-407, 2007 (Pubitemid 47181694)
16. Cullen M: Second-line treatment options in advanced non-small cell lung cancer: Current status. Semin Oncol 33:S3-S8, 2006 (suppl 1)
17. Hanna N, Shepherd FA, Fossella FV, et al: Randomised phase III trial of pemetrexed versus docetaxel in patients with advanced non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
18. Stinchcombe, Thomas E, Socinski, Mark A: Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13: 28-36, 2008
19. Gridelli C, Maione P: Advanced non-small cell lung cancer: Second line treatment with docetaxel in methods of cancer diagnosis, therapy and prognosis, in Hayat MA (ed): Medicine & Public Health, Oncology, Surgical Oncology, Nursing and Radiotherapy (vol 2). Dordrecht, the Netherlands, Springer Netherlands, 2008, pp 269-280
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previous treated non-small cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
21. Ramlau R, Gervais R, Krzakowski M, et al: Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24:2800-2807, 2006 (Pubitemid 46630579)
22. Esteban E, Gonzalez de Sande L, Fernandez Y, et al: Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 14:1640-1647, 2003 (Pubitemid 37455813)
23. Bonomi P, Paz-Ares L, Langer C, et al: Xyotax™ vs. docetaxel for the second-line treatment of non-small-cell lung cancer (NSCLC): The STELLAR 2 phase III study. Lung Cancer 49:35, 2005(suppl 2; abstr 099)
24. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
25. Cohen MH, Johnson JR, Wang YC, et al: FDA approval summary: Pemetrexed for injection (Alimta®) for treatment of non-small cell lung cancer. Oncologist 10:363-368, 2005 (Pubitemid 40993563)
26. Leighl NB, Shepherd FA, Kwong R, et al: Economic analysis of the 317 trial: Docetaxel versus BSC as second-line therapy of advanced non-small cell lung cancer. J Clin Oncol 20:1344-1352, 2002 (Pubitemid 34177441)